Prevention of CF Exacerbation in Childhood: PREVEC Study
Pulmonary exacerbations of CF are an important cause for the experienced disability of patients, respiratory symptoms, and decreases in lungfunction, which require antibiotic therapy at home or in the hospital. Therefore, prevention of exacerbations in CF is important. The aim of this study was to assess the predictive properties of inflammatory markers in exhaled breath for pulmonary exacerbations in children with CF. In addition the reliability of home monitor assessments of symptoms and lungfunction was investigated.
Exhaled Breath Condensate
Non-invasive Inflammatory Markers
Volatile Organic Compounds
Quality of Life
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Prevention of CF Exacerbation in Childhood (PREVEC): Early Recognition of Inflammation by Non-invasive Biomarkers in Exhaled Breath (Condensate)|
- Number of exacerbations [ Time Frame: 1 year ] [ Designated as safety issue: No ]Definition of an exacerbation according to Treggiari MM et al.
- Quality of life [ Time Frame: 1 year ] [ Designated as safety issue: No ]Quality of life questionnaire
|Study Start Date:||October 2011|
|Study Completion Date:||July 2014|
|Primary Completion Date:||August 2013 (Final data collection date for primary outcome measure)|
Children with Cystic Fibrosis, care as usual
Treatment according to the Dutch Central Guidance Committee (CBO) guidelines for CF. Assessments: home monitoring, symptoms, lung function, quality of life and diagnostic assessments of non-invasive inflammatory markers in exhaled air and exhaled breath condensate.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01241890
|Academic Medical Centre|
|Maastricht University Medical Centre|
|University Medical Centre|
|Principal Investigator:||E Dompeling, PhD MD||Maastricht University Medical Centre|